Unlicensed and off-label drug use: issues and recommendations

Area of Science:

• Pediatric pharmacology
• Drug regulation
• Patient safety

Background:

• Adult medications are licensed and regulated for safety and efficacy.
• Children frequently receive medications that are unlicensed or used off-label.
• This practice poses risks due to lack of adequate pediatric-specific data.

Purpose of the Study:

• To highlight the disparity in medication standards between adults and children.
• To underscore the need for improved access to well-tolerated and effective pediatric medicines.
• To advocate for regulatory changes and research initiatives in pediatric drug therapy.

Main Methods:

• Review of current practices in pediatric drug prescription.
• Analysis of the implications of using unlicensed and off-label medications in children.
• Examination of legislative and incentive-based approaches to pediatric drug research.

Main Results:

• Unlicensed and off-label drug use in children is widespread and includes essential medicines.
• Lack of pediatric-specific data leads to formulation issues, poor prescribing information, and increased adverse events.
• The US has implemented policies to encourage pediatric clinical trials.

Conclusions:

• Current practices for pediatric medication access are unacceptable and inequitable.
• Pediatric clinical trials are crucial for ensuring children receive safe and effective treatments.
• International collaboration and adoption of US-led initiatives are needed to improve pediatric pharmacotherapy.